Our company
Community Partnerships
Being a leader within the healthcare industry, GSK has taken the initiative to do its part for corporate social responsibility. Social responsibilities take top priority and this is especially evident in the programmes the company has set up and is actively involved in. In 2002, GSK spent £239 million supporting global community programs including product donations and charitable contributions.
The GSK Community Partnership encompasses a range of activities from healthcare and education to arts projects and scientific and medical research aimed at the betterment not only of the company’s employees but also the general public. On a global scale, the company is also involved in a host of schemes to combat health problems in the developing world via monetary and product donations, and employee involvement.
HIV/AIDS and Positive Action
GSK co-operates with UNAIDS and UNICEF in programmes aimed at facilitating access to treatment and preventing the maternal transmission of HIV to babies. The company was the first to offer preferential prices for its anti-retroviral drugs in developing countries enabling more patients to benefit. It is involved in HIV education, patient care and a program called Positive Action, which has led on to projects with the Centre for African Family Studies aimed at increasing awareness of people living with HIV/AIDS throughout Africa.
Eliminating Lymphatic Filariasis
GSK and the WHO have embarked on one of the most ambitious health programmes ever undertaken with the aim of eliminating lymphatic filariasis (elephantiasis) – a disabling and disfiguring parasitic disease affecting 120 million people worldwide. The company has committed to donating its drug Albendazole and providing financial support for as long as it takes to eliminate the disease.
Malaria
Through the African Malaria Partnership, GSK supports communities in their fight against malaria by awarding grants of up to US$1.5 million over three years to selected development programs.
Access to Vaccines
Essential vaccines are made available to charities and agencies like UNICEF and the WHO, which purchase large quantities for use in global programmes for the immunization of children.
In 2002, GSK spent £239 million supporting global community programmes including product donations and charitable contributions.
With all these figures, one can see that not only is GSK a leader in the industry, but is also committed to its mission of improving the quality of human life by enabling people to do more, feel better, and live longer.

